Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    10364231 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer
Conditions: Neoplasms;   Lymphoma
Interventions: Drug: ABT-888;   Drug: Cyclophosphamide
2 Completed Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
Conditions: Solid Tumors;   Lymphomas
Interventions: Drug: ABT-888;   Drug: Topotecan

Indicates status has not been verified in more than two years